



TTK Healthcare
LIMITED

TTKHC:SEC:SL:307:23

November 03, 2023

BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai 400 001

National Stock Exchange of India Limited
Exchange Plaza
Bandra Kurla Complex
Bandra East
Mumbai 400 051

SCRIP CODE: 507747

SCRIP CODE: TTKHLTCARE

Dear Sirs,

**Re : Disclosure under Regulation 30 - Unaudited Financial Results along with Limited
Review Report for the Second Quarter and Half-Year ended 30th September, 2023**

We are forwarding herewith the Unaudited Financial Results along with the Limited Review Report from the Statutory Auditors of the Company, for the Second Quarter and Half-Year ended 30th September, 2023, duly reviewed by the Audit Committee at their meeting held yesterday (i.e.) on 2nd November, 2023 and approved by the Board of Directors of the Company at their Meeting held today.

The Board Meeting commenced at 12 noon and concluded at 1.10 p.m.

Kindly take the above documents on record.

Thanking you

Yours faithfully
For TTK Healthcare Limited

(S KALYANARAMAN)
Wholetime Director & Secretary

Encl.: a/a



TTK HEALTHCARE LIMITED

Regd. Office : No.6, Cathedral Road, Chennai 600 086
 CIN: L24231TN1958PLC003647 | Website: www.ttkhealthcare.com

STATEMENT OF UNAUDITED FINANCIAL RESULTS
FOR THE QUARTER AND HALF YEAR ENDED 30TH SEPTEMBER, 2023
 [Prepared in compliance with the Indian Accounting Standards (Ind AS)]

		(Rs. in lakhs)					
Sl. No.	Particulars	For the Quarter ended			For the Half-year ended		For the Year ended
		(30/09/2023)	(30/06/2023)	(30/09/2022)	(30/09/2023)	(30/09/2022)	(31/03/2023)
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
I.	Revenue from Operations	18,576.68	20,212.35	16,979.18	38,789.03	36,241.21	72,511.03
II.	Other Income	1,603.01	1,461.34	1,106.28	3,064.35	2,092.51	4,833.17
III.	Total Income (I + II)	20,179.69	21,673.69	18,085.46	41,853.38	38,333.72	77,344.20
IV.	Expenses:						
	(a) Cost of materials consumed	4,608.75	4,523.01	4,596.36	9,131.76	8,926.42	18,228.65
	(b) Purchase of Stock-in-trade	3,885.95	4,385.20	3,868.00	8,271.15	8,254.75	17,020.75
	(c) Changes in inventories of Finished Goods, Work-in-progress and Stock-in-trade	(131.87)	(401.38)	(114.43)	(533.25)	437.98	(471.90)
	(d) Employee benefits expense	3,383.52	3,444.13	3,124.81	6,827.65	6,344.96	12,338.20
	(e) Finance Costs	73.12	85.99	79.61	159.11	350.52	523.89
	(f) Depreciation and Amortization Expense	327.81	315.58	332.08	643.39	651.83	1,280.64
	(g) Other Expenses	5,876.84	7,257.30	5,105.44	13,134.14	11,502.14	22,260.41
	Total Expenses (IV)	18,024.12	19,609.83	16,991.87	37,633.95	36,468.60	71,180.64
V.	Profit / (Loss) before Exceptional Items and Tax (III - IV)	2,155.57	2,063.86	1,093.59	4,219.43	1,865.12	6,163.56
VI.	Exceptional Items	-	-	-	-	-	-
VII.	Profit / (Loss) before Tax (V - VI)	2,155.57	2,063.86	1,093.59	4,219.43	1,865.12	6,163.56
VIII.	Tax Expense:						
	(1) Current Tax	580.00	530.00	333.00	1,110.00	611.08	1,741.03
	(2) Deferred Tax	(25.07)	(33.05)	(30.77)	(58.12)	28.82	(44.26)
IX.	Profit / (Loss) for the period from Continuing Operations (VII-VIII)	1,600.64	1,566.91	791.36	3,167.55	1,225.22	4,466.79
X.	Profit / (Loss) from Discontinued Operations [Refer Note No.3 (a) below]	-	-	-	-	77,643.92	77,643.92
XI.	Tax Expense from Discontinued Operations [Refer Note No.3 (b) below]	-	-	(199.95)	-	17,791.74	18,139.42
XII.	Profit / (Loss) from Discontinued Operations (after tax) (X - XI)	-	-	199.95	-	59,852.18	59,504.50
XIII.	Profit / (Loss) for the period (IX + XII)	1,600.64	1,566.91	991.31	3,167.55	61,077.40	63,971.29
XIV.	Other Comprehensive Income:						
	(A) (i) Items that will not be reclassified subsequently to profit or loss	59.36	98.18	235.04	157.54	233.82	(195.62)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	(8.61)	(6.02)	(26.89)	(14.63)	(26.75)	12.63
	(B) (i) Items that will be reclassified subsequently to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
XV.	Total Comprehensive Income for the period (XIII + XIV) [Comprising Profit / (Loss) and Other Comprehensive Income for the period] including Human Pharma Operations - Discontinued	1,651.39	1,659.07	1,199.46	3,310.46	61,284.47	63,788.30

	Paid-up Equity Share Capital (Face Value Rs.10 per share)	1,413.03	1,413.03	1,413.03	1,413.03	1,413.03	1,413.03
	Other Equity as per Balance Sheet (excluding Revaluation Reserve)	-	-	-	-	-	93,483.95
XVI.	Earnings per Equity Share (For Continuing Operations):						
(1)	Basic (in Rs.)	11.33	11.09	5.60	22.42	8.67	31.61
(2)	Diluted (in Rs.)	11.33	11.09	5.60	22.42	8.67	31.61
XVII.	Earnings per Equity Share (For Human Pharma Operations - Discontinued):						
(1)	Basic (in Rs.)	-	-	1.42	-	423.57	421.11
(2)	Diluted (in Rs.)	-	-	1.42	-	423.57	421.11
XVIII.	Earnings per Equity Share (For Continuing and Human Pharma Operations - Discontinued):						
(1)	Basic (in Rs.)	11.33	11.09	7.02	22.42	432.24	452.72
(2)	Diluted (in Rs.)	11.33	11.09	7.02	22.42	432.24	452.72

Notes:

- (1) The above financial results for the Second Quarter and Half-year ended 30th September, 2023 in respect of TTK Healthcare Limited (the Company) have been reviewed by the Audit Committee at its meeting held on 2nd November, 2023 and approved by the Board of Directors of the Company at its meeting held on 3rd November, 2023 at the Registered Office of the Company, also with the provision of Video Conferencing facility.
- (2) The Statutory Auditors of the Company have carried out Limited Review of the above Unaudited Financial Results in terms of Regulations 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- (3) (a) Profit from Discontinued Operations (pertaining to previous year)
 - (i) Gain on sale of undertaking:

During the First Quarter of FY 2022-23, the necessary formalities for transfer of the Human Pharma Division (Undertaking) of the Company were completed and the division stood transferred as a going concern on slump sale basis, for a consideration of Rs.80,500 lakhs (final consideration of Rs.80,281.54 lakhs after working capital and other customary adjustments) to M/s.BSV Pharma Private Ltd (BSV) with effect from 9th May, 2022

The consideration for the transfer was 74% cash (Rs.59,442.51 lakhs) and 26% in the form of equity of the buying entity. The terms of transfer also provided for purchase of the aforesaid 26% Equity Shares held by the Company in BSV, by M/s Bharat Serums and Vaccines Limited or its nominees, after they obtain necessary regulatory clearances at the issue price.

During the third quarter of FY 2022-23, the above shares were transferred to M/s Bharat Serums and Vaccines Limited and the consideration of Rs.20,839.03 lakhs for the shares was received by the Company.

The gain on sale of this Undertaking amounted to Rs.76,429.45 lakhs (after providing for Rs.1,500.00 lakhs towards contingencies of which Company had incurred expenses amounting to Rs.266.58 lakhs till 31st March, 2023).
 - (ii) Profit from Human Pharma Division Operations:

The total income of Human Pharma Division up to the date of sale (i.e.) 9th May, 2022 was Rs.2,240.57 lakhs (including reversal of provision made towards damaged / expired stock returns in the earlier years amounting to Rs.1,132.29 lakhs which was no longer required) and its total expenses were Rs.1,026.10 lakhs resulting in a net profit of Rs.1,214.47 lakhs.
- (b) Tax expense of Discontinued Operations (pertaining to previous year):

The tax expense on sale of Human Pharma Division was Rs.17,835.48 lakhs (i.e. Long Term Capital Gain tax expense on the above transfer amounting to Rs.17,769.26 lakhs and Deferred Tax expenses of Rs.66.22 lakhs).

The tax expense on the profit for the year ended 31st March, 2023 from the operations of Human Pharma Division was Rs.303.94 lakhs.
- (4) Implementation of the Code of Social Security 2020, which is likely to impact the contributions by the Company towards Provident Fund, Gratuity and other related areas has been deferred by the Government beyond 1st April, 2021. However, the Company based on the initial assessment made a provision for Rs.350 lakhs in the Fourth Quarter of FY 2020-21 and proposes to take further appropriate action after the Rules are made applicable.
- (5) The previous period's / year's figures have been regrouped and reclassified, wherever necessary to conform to the current period's / year's presentation.
- (6) This statement is also available on the website of BSE Limited (www.bseindia.com), National Stock Exchange of India Limited (www.nseindia.com) and also on the website of the Company (www.ttkhealthcare.com).

(7) Statement of Assets and Liabilities as at 30th September, 2023:


(Rs. in lakhs)

Sl. No.	Particulars	As on	As on
		30/09/2023	31/03/2023
		Unaudited	Audited
(A)	ASSETS:		
I	Non-Current Assets:		
(a)	Property, Plant and Equipment	6,298.62	6,056.59
(b)	Right of Use Asset	1,361.27	1,058.74
(c)	Capital Work-in-Progress	160.19	278.87
(d)	Other Intangible Assets	1.82	3.66
(e)	Financial Assets		
(i)	Investments	1,442.34	1,284.80
(ii)	Others Financial Assets	393.76	387.57
(f)	Non-current Tax Assets (Net)	281.99	282.00
(g)	Deferred Tax Assets (Net)	479.46	435.97
(h)	Other Non-current Assets	112.31	615.39
	Total Non-Current Assets	10,531.76	10,403.59
II	Current Assets:		
(a)	Inventories	8,952.11	8,451.46
(b)	Financial Assets		
(i)	Investments	-	-
(ii)	Trade Receivables	9,235.48	9,209.91
(iii)	Cash and Cash Equivalents	765.23	932.03
(iv)	Bank balances other than (iii) above	83,731.26	83,783.97
(v)	Other Financial Assets	3,232.73	2,418.29
(c)	Other Current Assets	1,779.05	1,811.83
	Total Current Assets	1,07,695.86	1,06,607.49
	TOTAL ASSETS	1,18,227.62	1,17,011.08
(B)	EQUITY AND LIABILITIES:		
(1)	Equity		
(a)	Equity Share Capital	1,413.03	1,413.03
(b)	Other Equity	95,822.81	93,925.38
	Equity attributable to owners of the Company	97,235.84	95,338.41
	Total Equity	97,235.84	95,338.41
(2)	Liabilities		
	Non-current Liabilities:		
(a)	Financial Liabilities:		
(i)	Lease Liabilities	92.40	121.49
(b)	Provisions	430.86	302.83
(c)	Deferred Revenue Income	-	170.36
	Total Non-current Liabilities	523.26	594.68
	Current Liabilities:		
(a)	Financial Liabilities		
(i)	Borrowings	2,337.38	2,552.83
(ia)	Lease Liabilities	59.43	58.55
(ii)	Trade Payables:		
(A)	Total outstanding due of Micro Enterprises and Small Enterprises	1,788.83	2,446.41
(B)	Total outstanding due of creditors other than Micro Enterprises and Small Enterprises	10,294.11	9,999.56
(iii)	Other Financial Liabilities	4,660.15	4,926.75
(b)	Other Current Liabilities	328.95	364.11
(c)	Provisions	383.30	478.03
(d)	Current Tax Liabilities (Net)	616.37	251.75
	Total Current Liabilities	20,468.52	21,077.99
	TOTAL LIABILITIES	20,991.78	21,672.67
	TOTAL EQUITY AND LIABILITIES	1,18,227.62	1,17,011.08

(8) Statement of Cash Flow for the Half-year ended 30th September, 2023:

Particulars	(Rs. in lakhs)		
	For the Half-year ended	For the Half-year ended	For the year ended
	(30/09/2023)	(30/09/2022)	(31/03/2023)
	Unaudited	Unaudited	Audited
Cash Flow from Operating activities:			
Profit Before tax from Continuing Operations	4,219.43	1,865.12	6,163.56
Profit Before tax from Human Pharma Operations	-	77,643.92	77,643.92
Profit before tax for Continuing Operations and Human Pharma Operations	4,219.43	79,509.04	83,807.48
Adjustments for:			
Remeasurements of defined benefit plans	-	-	33.05
Depreciation and amortisation Expenses	643.39	662.98	1,291.79
Provision for Doubtful Debts	17.91	(4.04)	(1.54)
Bad debts written off	-	3.43	40.99
Creditors written back	-	-	(8.60)
Interest paid	159.11	358.19	531.56
Interest received	(3,024.98)	(1,957.71)	(4,631.56)
(Profit) / Loss on Sale of Assets / Impairment	(8.67)	(0.51)	3.38
Dividend income	(10.75)	(6.33)	(6.39)
Un Realised Forex (Gain) / Loss	(0.87)	(18.04)	0.17
Reversal of Refund Liability provision	-	-	(1,132.29)
Gain from Sale of Human Pharma Undertaking (Net of Expenses)	-	(76,429.45)	(76,429.45)
Deferred Revenue Income	(170.36)	-	-
Operating Profit before working Capital Changes:	1,824.21	2,117.56	3,498.59
Adjustments for Working Capital changes:			
Inventories	(500.65)	1,044.02	191.00
Trade receivables	(42.61)	(660.22)	(2,230.32)
Other Receivables	35.58	(112.96)	(701.75)
Trade payables	(363.03)	(164.31)	192.92
Other liabilities	(224.42)	(3,262.95)	(1,949.52)
Deferred Revenue Income	-	(18.39)	(18.42)
Cash generated from Operations	729.08	(1,057.25)	(1,017.50)
Less: Direct Taxes Paid	745.38	434.67	2,037.64
Add: Direct Taxes Received	-	349.88	447.52
Net Cash generated from (used in) Operating Activities	(16.30)	(1,142.04)	(2,607.62)
Cash Flow from Investing Activities:			
Purchase of Property, Plant and Equipment, Other Intangible Assets and Capital advances	(595.37)	(225.03)	(1,169.91)
Proceeds from the sale of Property, Plant and Equipment and Other Intangible Assets (other than Right of Use Asset)	8.95	6.48	10.17
Proceeds from the sale of Right of Use Asset	-	-	15.86
Sale Proceeds of Human Pharma Division (Net of Expenses)	-	56,901.62	77,531.33
Direct Tax on Sale of Human Pharma Undertaking	-	(8,076.00)	(17,769.26)
Investments in Bank deposits (Net)	52.71	(33,108.66)	(57,919.63)
Interest received	2,201.55	1,190.67	2,590.91
Dividend Received	10.75	6.33	6.39
Net Cash generated from (used in) Investing Activities	1,678.59	16,695.41	3,295.86
Cash Flow from Financing Activities:			
Borrowings (Net of repayment)	(215.45)	102.28	514.39
Principal repayment of Lease Liabilities	(28.21)	9.11	(54.77)
Interest Paid on other than Lease Activity	(160.42)	(337.70)	(260.40)
Interest Paid on Lease Activity	(11.98)	(15.49)	(28.82)
Dividend Paid	(1,413.03)	(1,413.03)	(1,413.03)
Net Cash generated from (used in) Financing Activities	(1,829.09)	(1,654.83)	(1,242.63)
Net Increase / (Decrease) in Cash and Cash Equivalents	(166.81)	13,898.54	(554.39)
Cash and Cash Equivalents as at the beginning of the year	932.03	1,486.42	1,486.42
Total	765.23	15,384.96	932.03
Cash and Cash Equivalents as at the end of the year (as per Balance Sheet)	765.23	15,384.96	932.03

For TTK HEALTHCARE LIMITED



T T RAGHUNATHAN
Executive Chairman

Place : Chennai
Date : November 03, 2023



TTK HEALTHCARE LIMITED

Regd. Office : No.6, Cathedral Road, Chennai 600 086
CIN: L24231TN1958PLC003647 | Website: www.ttkhealthcare.com

SEGMENTWISE REVENUE, RESULTS, ASSETS & LIABILITIES FOR THE QUARTER AND HALF YEAR ENDED 30TH SEPTEMBER, 2023

		(Rs. in lakhs)					
Sl. No.	Particulars	For the Quarter ended			For the Half-year ended		For the Year ended
		(30/09/2023)	(30/06/2023)	(30/09/2022)	(30/09/2023)	(30/09/2022)	(31/03/2023)
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1.	Segment Revenue: (Sales and Other Operating Income)						
	(a) Animal Welfare	2,944.21	2,723.78	2,713.05	5,667.99	5,196.53	10,625.77
	(b) Consumer Products	5,390.31	7,117.66	5,660.00	12,507.97	13,245.31	24,127.01
	(c) Medical Devices	2,123.34	2,221.10	1,612.28	4,344.44	3,545.13	7,185.77
	(d) Protective Devices	5,012.73	5,146.94	4,268.47	10,159.67	8,790.62	19,386.02
	(e) Foods	3,093.93	2,990.13	2,714.88	6,084.06	5,440.81	11,150.57
	(f) Others	12.16	12.74	10.50	24.90	22.81	35.89
	(g) Human Pharma - Discontinued Operations	-	-	-	-	1,107.20	1,107.20
	Total	18,576.68	20,212.35	16,979.18	38,789.03	37,348.41	73,618.23
	Less : Inter Segment Revenue	-	-	-	-	-	-
	Net Sales / Income from Operations	18,576.68	20,212.35	16,979.18	38,789.03	37,348.41	73,618.23
2.	Segment Results: [Profit (+) / Loss (-) before tax and interest from each segment]						
	(a) Animal Welfare	217.30	129.21	172.57	346.51	257.88	684.94
	(b) Consumer Products	333.34	498.46	565.70	831.80	1,215.18	2,421.70
	(c) Medical Devices	480.91	580.09	239.35	1,061.00	539.80	1,219.36
	(d) Protective Devices	498.21	302.59	76.28	800.80	181.41	1,471.03
	(e) Foods	(158.74)	3.99	(146.51)	(154.75)	(282.87)	(498.09)
	(f) Others	8.08	9.92	8.05	18.00	15.24	27.97
	(g) Human Pharma - Discontinued Operations [Refer Note No.3 (a) below]	-	-	-	-	77,651.59	77,651.59
	Total	1,379.10	1,524.26	915.44	2,903.36	79,578.23	82,978.50
	Less : Finance Cost	73.12	85.99	79.61	159.11	358.19	531.56
	Less : Unallocable Expenses (Net of Unallocable Income)	(849.59)	(625.59)	(257.76)	(1,475.18)	(289.00)	(1,360.54)
	Total Profit (+) / Loss (-) before tax	2,155.57	2,063.86	1,093.59	4,219.43	79,509.04	83,807.48
		As on 30/09/2023	As on 30/06/2023	As on 30/09/2022	As on 30/09/2023	As on 30/09/2022	As on 31/03/2023
3.	Segment Assets:						
	(a) Animal Welfare	3,915.86	4,166.46	4,110.97	3,915.86	4,110.97	3,779.27
	(b) Consumer Products	4,145.38	4,919.58	3,716.25	4,145.38	3,716.25	4,688.94
	(c) Medical Devices	6,794.97	7,079.53	5,430.18	6,794.97	5,430.18	6,132.89
	(d) Protective Devices	12,056.31	12,015.97	9,697.63	12,056.31	9,697.63	11,855.40
	(e) Foods	6,834.70	7,783.75	8,688.59	6,834.70	8,688.59	7,780.97
	(f) Others	256.39	242.70	219.03	256.39	219.03	230.93
	Total	34,003.61	36,207.99	31,862.65	34,003.61	31,862.65	34,468.40
	Unallocated [Refer Note No.3 (b) below]	84,224.01	84,170.66	91,925.68	84,224.01	91,925.68	82,542.68
	Total Assets	1,18,227.62	1,20,378.65	1,23,788.33	1,18,227.62	1,23,788.33	1,17,011.08
4.	Segment Liabilities:						
	(a) Animal Welfare	3,334.30	3,607.77	4,925.40	3,334.30	4,925.40	3,328.10
	(b) Consumer Products	6,427.86	7,184.74	6,041.62	6,427.86	6,041.62	6,644.30
	(c) Medical Devices	1,705.25	2,369.89	2,057.54	1,705.25	2,057.54	1,725.66
	(d) Protective Devices	3,754.49	4,385.33	3,719.57	3,754.49	3,719.57	4,181.85
	(e) Foods	1,329.58	1,505.53	1,627.22	1,329.58	1,627.22	1,492.82
	(f) Others	134.47	133.72	133.47	134.47	133.47	134.07
	Total	16,685.95	19,186.98	18,504.82	16,685.95	18,504.82	17,506.80
	Unallocated	4,305.83	4,194.19	12,448.93	4,305.83	12,448.93	4,165.87
	Total Liabilities	20,991.78	23,381.17	30,953.75	20,991.78	30,953.75	21,672.67

Notes:

1. Segments have been identified in line with the Indian Accounting Standard on Segment Reporting (Ind AS 108) based on review of performance by the Top Management.
2. Details of products included in each of the Segments are as below :
 - ❖ Animal Welfare (earlier included in Pharmaceuticals Segment) comprise products for Veterinary use.
 - ❖ Consumer Products comprise marketing and distribution of Woodward's Gripewater, EVA Range of Cosmetics, Good Home range of Scrubbers, Air Fresheners, etc.
 - ❖ Medical Devices include Artificial Heart Valves, Orthopaedic Implants, etc.
 - ❖ Protective Devices comprise manufacturing and marketing of Male Contraceptives and other allied products.
 - ❖ Foods comprise manufacturing and marketing of Food Products.
 - ❖ "Others" include Printing and Publishing of Maps and Atlases.
 - ❖ Human Pharma (earlier included in Pharmaceuticals Segment) comprise products for Human use
3. (a) Segment Results of Human Pharma Division include gain on sale of the division amounting to Rs.76,429.45 lakhs.
(b) Unallocated Segment Assets include consideration on sale of Human Pharma Division received in the form of cash and equity.
4. The segment wise revenue, results, assets and liabilities figures relate to respective amounts directly identifiable to each of the segments. The unallocable expenditure includes expenses incurred on common services at the corporate level and also those expenses not identifiable to any specific segment.
5. The previous period's / year's figures have been regrouped and reclassified, wherever necessary to conform to the current period's / year's presentation.

For TTK HEALTHCARE LIMITED



T T RAGHUNATHAN
Executive Chairman

Place : Chennai
Date : November 03, 2023

**TTK HEALTHCARE LIMITED**

Regd. Office : No.6, Cathedral Road, Chennai 600 086
 CIN: L24231TN1958PLC003647 | Website: www.ttkhealthcare.com

**EXTRACT OF UNAUDITED FINANCIAL RESULTS
 FOR THE QUARTER AND HALF YEAR ENDED 30TH SEPTEMBER, 2023**

Sl. No.	Particulars	(Rs. in lakhs)					
		For the Quarter ended			For the Half-year ended		For the Year ended
		(30/09/2023)	(30/06/2023)	(30/09/2022)	(30/09/2023)	(30/09/2022)	(31/03/2023)
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited	
1.	Total income from Operations	18,576.68	20,212.35	16,979.18	38,789.03	37,348.41	73,618.23
2.	Net Profit / (Loss) for the period (before Tax, Exceptional and / or Extraordinary Items)	2,155.57	2,063.86	1,093.59	4,219.43	79,509.04	83,807.48
3.	Net Profit / (Loss) for the period before Tax (after Exceptional and / or Extraordinary Items)	2,155.57	2,063.86	1,093.59	4,219.43	79,509.04	83,807.48
4.	Net Profit / (Loss) for the period after Tax (after Exceptional and / or Extraordinary Items)	1,600.94	1,566.91	991.31	3,167.55	61,077.40	63,971.29
5.	Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after Tax) and Other Comprehensive Income (after Tax)]	1,651.39	1,659.07	1,199.46	3,310.46	61,284.47	63,788.30
6.	Equity Share Capital (Face Value of Rs.10/- per share)	1,413.03	1,413.03	1,413.03	1,413.03	1,413.03	1,413.03
7.	Other Equity as per Balance Sheet of previous accounting year (excluding Revaluation Reserve)	-	-	-	-	-	93,483.95
8.	Earnings per share (of Rs.10/- each) (for Continuing and Discontinued operations)						
	(a) Basic (in Rs.)	11.33	11.09	7.02	22.42	432.24	452.72
	(b) Diluted (in Rs.)	11.33	11.09	7.02	22.42	432.24	452.72

Notes:

- (1) The above is an extract of the detailed Statement of Unaudited Financial Results for the Second Quarter and Half-year ended 30th September, 2023, filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
 - (2) The full financial results for the Second Quarter and Half-year ended 30th September, 2023 are available on the website of BSE Limited (www.bseindia.com), National Stock Exchange of India Limited (www.nseindia.com) and also on the website of the Company (www.ttkhealthcare.com).
 - (3) The above financial results for the Second Quarter and Half-year ended 30th September, 2023 in respect of TTK Healthcare Limited (the Company) have been reviewed by the Audit Committee at its meeting held on 2nd November, 2023 and approved by the Board of Directors of the Company at its meeting held on 3rd November, 2023 at the Registered Office of the Company, also with the provision of Video Conferencing facility.
 - (4) The Statutory Auditors of the Company have carried out Limited Review of the above Unaudited Financial Results in terms of Regulations 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
 - (5) (a) Profit from Discontinued Operations (pertaining to previous year)
 - (i) Gain on sale of undertaking:

During the First Quarter of FY 2022-23, the necessary formalities for transfer of the Human Pharma Division (Undertaking) of the Company were completed and the division stood transferred as a going concern on slump sale basis, for a consideration of Rs.80,500 lakhs (final consideration of Rs.80,281.54 lakhs after working capital and other customary adjustments) to M/s.BSV Pharma Private Ltd (BSV) with effect from 9th May, 2022

The consideration for the transfer was 74% cash (Rs.59,442.51 lakhs) and 26% in the form of equity of the buying entity. The terms of transfer also provided for purchase of the aforesaid 26% Equity Shares held by the Company in BSV, by M/s Bharat Serums and Vaccines Limited or its nominees, after they obtain necessary regulatory clearances at the issue price.

During the third quarter of FY 2022-23, the above shares were transferred to M/s Bharat Serums and Vaccines Limited and the consideration of Rs.20,839.03 lakhs for the shares was received by the Company.


The gain on sale of this Undertaking amounted to Rs.76,429.45 lakhs (after providing for Rs.1,500.00 lakhs towards contingencies of which Company had incurred expenses amounting to Rs.266.58 lakhs till 31st March, 2023).
 - (ii) Profit from Human Pharma Division Operations:

The total income of Human Pharma Division up to the date of sale (i.e.) 9th May, 2022 was Rs.2,240.57 lakhs (including reversal of provision made towards damaged / expired stock returns in the earlier years amounting to Rs.1,132.29 lakhs which was no longer required) and its total expenses were Rs.1,026.10 lakhs resulting in a net profit of Rs.1,214.47 lakhs.
 - (b) Tax expense of Discontinued Operations (pertaining to previous year):

The tax expense on sale of Human Pharma Division was Rs.17,835.48 lakhs (i.e. Long Term Capital Gain tax expense on the above transfer amounting to Rs.17,769.26 lakhs and Deferred Tax expenses of Rs.66.22 lakhs).

The tax expense on the profit for the year ended 31st March, 2023 from the operations of Human Pharma Division was Rs.303.94 lakhs.
- (6) Implementation of the Code of Social Security 2020, which is likely to impact the contributions by the Company towards Provident Fund, Gratuity and other related areas has been deferred by the Government beyond 1st April, 2021. However, the Company based on the initial assessment made a provision for Rs.350 Lakhs in the Fourth Quarter of FY 2020-21 and proposes to take further appropriate action after the Rules are made applicable.
- (7) The previous period's / year's figures have been regrouped and reclassified, wherever necessary to conform to the current period's / year's presentation.

For TTK HEALTHCARE LIMITED


T T RAGHUNATHAN
 Executive Chairman

Place : Chennai
 Date : November 03, 2023

PKF SRIDHAR & SANTHANAM LLP

Chartered Accountants

Independent Auditor's Review Report on review of Interim Financial Results

To the Board of Directors of TTK Healthcare Limited

1. We have reviewed the accompanying statement of unaudited financial results of **TTK Healthcare Limited** (the "Company"), for the quarter and half year ended 30th September 2023 ("the Statement"), being submitted by the Company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Obligations") which has been initialed by us for identification.

Management's Responsibility

2. This Statement which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India.

Auditor's Responsibility

3. Our responsibility is to issue a report on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410 'Review of Interim Financial Information performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Conclusion

4. Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with the aforesaid Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Obligations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **PKF Sridhar & Santhanam LLP**

Chartered Accountants

Firm's Registration No. 003990S/S200018


S. Rajeshwari

Partner

Membership No. 024105



Place: Chennai

Date: 03rd November 2023

UDIN: 23024105BGYMIZ7502